Recipharm, which picked up three plants two years ago with the buyout of Milan-based Corvette Pharmaceutical Services Group, is again expanding capabilities at one of them.
The Sweden-based company says it will invest about $1.3 million (€1.2 million) to expand its small-scale GMP active pharmaceutical ingredient (API) development and manufacturing capabilities at the Paderno Dugnano facility.
Matteo Zacché, R&D manager for Recipharm in Paderno Dugnano, said that with the addition of the new laboratory, the company can now run up to six customer projects in parallel and handle maximum batch sizes of approximately 5 kg. Previously the lab could handle only about 1-kg batch sizes.
The facility also added new technology in flow chemistry, chromatography and other capabilities, he said. As a result of the expansion, the company also plans to increase the R&D staff to eight from the four employees currently working there.
Recipharm paid about $164.5 million two years ago to buy Corvette from the Italian private equity group LBO Italia Investimenti. In addition to the plant in Paderno Dugnano, API and finished dose form development and manufacturing, it got a sterile injectables facility in Masate and a plant in Lainate that does bulk lyophilisation of sterile beta lactam antibiotics.
In August, Recipharm said it was investing about $4.2 million (€3.7 million) in Masate, to boost its vial filling capacity by about 20%.